Drugging the HDAC6–HSP90 interplay in malignant cells

Highlights • HDAC6 has unique cytoprotective functions. • HDAC6 is a valid target for pharmacological intervention strategies. • The HDAC6–HSP90 interplay is more complex and important than anticipated. • An increasing number of PTMs controls HDAC6 and HSP90. • Certain structures determine the speci...

Full description

Saved in:
Bibliographic Details
Published in:Trends in pharmacological sciences (Regular ed.) 2014-10, Vol.35 (10), p.501-509
Main Authors: Krämer, Oliver H, Mahboobi, Siavosh, Sellmer, Andreas
Format: Article
Language:English
Subjects:
Acetylation
Advanced Basic Science
Animals
Antineoplastic Agents - pharmacology
cancer
HDAC6
HDAC6 inhibitor
Histone Deacetylase Inhibitors - pharmacology
Histone Deacetylases - metabolism
HSP90
HSP90 Heat-Shock Proteins - metabolism
Humans
leukemia
Molecular Targeted Therapy
Neoplasms - drug therapy
Neoplasms - enzymology
Neoplasms - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights • HDAC6 has unique cytoprotective functions. • HDAC6 is a valid target for pharmacological intervention strategies. • The HDAC6–HSP90 interplay is more complex and important than anticipated. • An increasing number of PTMs controls HDAC6 and HSP90. • Certain structures determine the specificity of drugs against HDAC6. • Future development of increasingly selective and potent HDAC6i is anticipated.
ISSN:0165-6147
1873-3735
DOI:10.1016/j.tips.2014.08.001